Ascendis Pharma A/S experienced significant sales growth in 2025 and anticipates a new product approval in 2026. This growth positions Ascendis to compete more directly with BioMarin Pharmaceutical Inc. The article suggests that Ascendis is continuing its positive trajectory in the market.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story
Ascendis Pharma A/S experienced significant sales growth in 2025 and anticipates a new product approval in 2026. This growth positions Ascendis to compete more directly with BioMarin Pharmaceutical Inc. The article suggests that Ascendis is continuing its positive trajectory in the market.